Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 307943, 8 pages
http://dx.doi.org/10.1155/2015/307943
Clinical Study

Pretreatment Diffusion-Weighted MRI Can Predict the Response to Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma

1Cancer Center, Cancer Research Institute, Foshan Hospital, Sun Yat-sen University, Foshan, Guangdong 528000, China
2Imaging Diagnosis Center, Foshan Hospital, Sun Yat-sen University, Foshan, Guangdong 528000, China
3Department of Radiation Oncology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China

Received 22 August 2014; Revised 31 March 2015; Accepted 1 April 2015

Academic Editor: Zhengchao Dong

Copyright © 2015 Guo-Yi Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To explore the potential of diffusion-weighted (DW) magnetic resonance imaging (MRI) using apparent diffusion coefficient (ADC) for predicting the response to neoadjuvant chemotherapy in nasopharyngeal carcinoma (NPC). Methods and Materials. Ninety-two consecutive patients with NPC who underwent three cycles of neoadjuvant chemotherapy were retrospectively analyzed. DW and anatomical MRI were performed before and after neoadjuvant chemotherapy prior to radiotherapy. Pretreatment ADCs and percentage increases in ADC after chemotherapy were calculated for the primary lesions and metastatic adenopathies. Receiver operating characteristic curve analysis was used to select optimal pretreatment ADCs. Results. Pretreatment mean ADCs were significantly lower for responders than for nonresponders (primary lesions, ; metastatic adenopathies, ). Mean percentage increases in ADC were higher for responders than for nonresponders (primary lesions, ; metastatic adenopathies, ). The optimal pretreatment primary lesion and metastatic adenopathy ADCs for differentiating responders from nonresponders were 0.897 × 10−3 mm2/sec and 1.031 × 10−3 mm2/sec, respectively. Conclusions. NPC patients with low pretreatment ADCs tend to respond better to neoadjuvant chemotherapy. Pretreatment ADCs could be used as a new pretreatment imaging biomarker of response to neoadjuvant chemotherapy.